v3.25.1
Collaboration Agreement (Details)
$ in Thousands
1 Months Ended 3 Months Ended
Dec. 31, 2021
USD ($)
target
program
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2024
USD ($)
Sep. 30, 2023
Collaborative Arrangement and Arrangement Other than Collaborative          
Revenue   $ 5,952 $ 5,050    
Accrued expenses and other current liabilities   6,454   $ 8,531  
Eli Lilly          
Collaborative Arrangement and Arrangement Other than Collaborative          
Number of programs | program 6        
Number of targets | target 5        
Cost sharing allocation 50.00%       50.00%
Deferred revenue   274,100      
Eli Lilly | Related Party          
Collaborative Arrangement and Arrangement Other than Collaborative          
Revenue   6,000 5,100    
Eli Lilly | Related Party | Lilly Collaboration Agreement          
Collaborative Arrangement and Arrangement Other than Collaborative          
Revenue   600 $ 1,700    
Accrued expenses and other current liabilities   $ 1,400   $ 600  
Eli Lilly | Sales Based Milestone          
Collaborative Arrangement and Arrangement Other than Collaborative          
Amount receivable for achievement of milestones $ 180,000        
Optout milestone receivable upon achievement 360,000        
Eli Lilly | Maximum | Research Development and Regulatory          
Collaborative Arrangement and Arrangement Other than Collaborative          
Amount receivable for achievement of milestones 10,000        
Optout milestone receivable upon achievement $ 70,000        
Eli Lilly | Joint Programs          
Collaborative Arrangement and Arrangement Other than Collaborative          
Number of programs | program 2        
Number of targets | target 1        
Eli Lilly | Discovery Programs          
Collaborative Arrangement and Arrangement Other than Collaborative          
Number of additional targets | target 3